Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007201
Chunk: 17

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 17
---
as defined below) at a 
 weighted average exercise price of $877.13 per share; and                                                                         |

| · | warrants, including pre-funded warrants, exercisable for 770,026 Depositary Shares (representing 7,700,260,000 Ordinary Shares), at 
 a weighted average exercise price of $38.42 per Depositary Share.                                                                   |

| 14 |

<div align='center'>DESCRIPTION OF OFFERED SECURITIES AND SHARE CAPITAL</div>

The following describes our issued share capital, summarizes the material provisions of our Articles of Association and highlights certain differences in corporate law in the United Kingdom and the United State. This description of our share capital and summary of our Articles of Association is not complete, and is qualified by reference to our Articles of Association. You should read our Articles of Association, which are filed as an exhibit to the registration statement of which this prospectus forms a part, for the provisions that are important to you.

General

We are a public limited company
organized under the laws of England and Wales under registered number 09216368. Our registered office is 1 Caspian Point, Caspian Way,
Cardiff, CF10 4DQ, United Kingdom. The principal legislation under which we operate and our shares are issued is the United Kingdom Companies
Act of 2006, or the Companies Act.

Issued Share Capital

Our issued share capital as
of December 31, 2024 and April 1, 2025 was 6,685,918,822 Ordinary Shares and 25,617,408,922 Ordinary Shares, respectively, with each Ordinary
Share having a nominal value of £0.00005 per share. Each issued Ordinary Share is fully paid. We currently have 1,000,001 A Deferred
Shares, 4,063,321,420 B Deferred Shares, 126,547,389,518 C Deferred Shares, and no preference shares in our issued share capital.

There is no limit to the number
of Ordinary Shares or preference shares that we are authorized to issue, as the concept of authorized capital is no longer applicable
under the provisions of the Companies Act. There are no conversion rights, redemption provisions or sinking fund provisions relating to
any Ordinary Shares.

We are not permitted under
English law to hold our own Ordinary Shares unless they are repurchased by us and held in treasury. We do not currently hold any of our
own Ordinary Shares.

History of Share Capital

Since January 1,